Can Endothelial Progenitor Cells Rescue Damaged Lungs?
"Exploring new frontiers in acute lung injury treatment."
Acute lung injury (ALI) remains a critical healthcare challenge, spurring the search for innovative treatments. Among these, endothelial progenitor cells (EPCs) have emerged as promising therapeutic agents. First identified in 1997, these cells offer potential in treating various diseases, including ALI, by aiding in tissue repair and reducing inflammation.
EPCs, derived from bone marrow, are characterized as CD34+/VEGFR2+/CD133+ cells. Their primary function involves repairing damaged vascular endothelium and promoting new blood vessel formation. This is achieved through direct differentiation into endothelial cells and the release of paracrine signals, such as vascular endothelial growth factor (VEGF) and stromal derived factor-1 (SDF-1).
Additionally, EPCs play a crucial role in modulating inflammatory responses by suppressing interleukin-1 beta (IL-1β), tumor necrosis factor-alpha (TNF-α), toll-like receptor 4, and IL-6. Recent studies have also highlighted the role of EPC-produced exosomes, containing microRNA (like miR-126), in alleviating lung injury. These findings suggest EPCs could offer a novel approach to managing lung inflammation and damage.
Promise and Uncertainty
The discovery of endothelial progenitor cells (EPCs) in 1997 introduced the concept of postnatal vasculogenesis and raised hopes for improving vascularization in fragile populations, including patients with bronchopulmonary dysplasia and alveolar capillary dysplasia with misalignment of pulmonary veins. Studies report that EPC transplantation may reduce inflammatory-cell adhesion and exudation in acute lung injury, while also noting that the mechanism of this inflammatory modulation remains unclear. Important unresolved questions include whether therapeutic benefit depends on cell engraftment or on immunomodulatory effects from paracrine molecules and microvesicles.
How EPCs Could Combat Respiratory Distress
Acute respiratory distress syndrome (ARDS) arises from widespread lung injury, leading to respiratory failure. Characterized by neutrophil influx and subsequent pro-inflammatory cascades, ARDS results in significant epithelial and endothelial damage. Despite medical advances, ARDS mortality remains high, underscoring the need for more effective treatments.
- EPCs in Focus: While MSCs show promise, EPCs also hold significant potential. They remain attractive as possible therapeutic agents for ARDS and sepsis, backed by supportive data from mouse models.
- Survival Link: Intriguingly, circulating EPC levels correlate with survival rates in ARDS patients, suggesting their therapeutic relevance.
- Journal Insights: A study by Mao et al. explores how EPCs protect against endotoxin-induced lung injury in mice, revealing their direct inhibitory effects on neutrophils.
A Field Still in Progress
The 2019 commentary by Sueblinvong and Weiss, titled “Acute Lung Injury: Endothelial Progenitor Cells to the Rescue?”, reflects continuing interest in EPCs as a possible treatment for acute lung injury. Its publication in The American Journal of the Medical Sciences shows that the question remained under active scientific discussion rather than representing an established clinical solution. The title itself frames EPC therapy as a promising but unresolved possibility.
EPCs Among Repair Strategies
Bone marrow-derived EPCs have been shown to attenuate lipopolysaccharide-induced acute lung injury in animal models, although the molecular mechanism is described as largely unknown. In contrast, lung-regeneration research emphasizes type 2 lung epithelial cells and airway epithelial cells, which can differentiate to replace damaged type 1 alveolar epithelial cells and help maintain lung function. Research on hyperoxia further reports that bone marrow, circulating, and lung EPCs are reduced in the developing lung, linking EPC availability to bronchopulmonary dysplasia research.
The Future of EPCs in Lung Injury Treatment
While research indicates EPCs can attenuate lung injury by reducing inflammation and tissue damage, questions remain regarding their precise mechanisms of action. Specifically, whether these effects are mediated through paracrine signaling or direct cell-cell interaction needs further exploration.
Repair Beyond Engraftment
Reviews describe endogenous and exogenous stem and progenitor cells as part of a broader toolbox for repairing injured lungs, while also identifying unresolved problems in pulmonary remodeling and regeneration. EPCs were first described in 1997 and are characterized in one review as circulating, bone marrow-derived CD34+/VEGFR2+/CD133+ cells that can repair damaged vascular endothelium and promote new vessel formation. In acute respiratory distress syndrome and acute lung injury, vascular endothelial and alveolar epithelial damage occur together, supporting the view that EPC-based strategies must be considered within a wider tissue-repair process.
Designing the Repair Environment
Recent outlooks describe lung repair as beginning with activation and proliferation of resident epithelial progenitor cells after chronic disease or acute injury; these cells can migrate, divide, and differentiate to replace damaged cells. Reviews also emphasize epithelial stem and progenitor populations, their plasticity and lineage trajectories, and the roles of mesenchymal, endothelial, and immune niche cells in regulating repair. Future work is therefore moving toward advanced models, including 3D systems, and toward therapies that account for endothelial heterogeneity, injury responses, environmental cues, and the alveolar niche.
From Models to Patients
Acute respiratory distress syndrome disrupts the alveolar-capillary barrier, causing proteinaceous edema and increased inflammatory cells in the alveolar space. In a reported sepsis context, exosomes from EPCs were found to prevent endothelial dysfunction and lung injury in part through their encapsulated contents. These findings suggest a possible cell-free route for translating EPC biology into treatments, although the evidence described comes from experimental research rather than established routine care.
The current research focuses on systemic endotoxin-induced lung injury without infection. Future studies should assess EPC effects in models that mimic clinical sepsis more closely, including bacterial infections and direct airway endotoxin administration. Understanding EPCs' effects on neutrophils and other inflammatory pathways is crucial for advancing their therapeutic application.
In summary, EPCs show promise for treating ARDS, potentially by leveraging their anti-inflammatory properties. Despite encouraging pre-clinical results, clinical trials are needed to confirm their efficacy in ARDS and sepsis. Further research elucidating how EPCs modulate neutrophil behavior in vitro and in vivo will pave the way for translating these findings into effective bedside treatments.